文献速递消化系统肿瘤

免疫检查点抑制剂治疗POLE或POLD1校对缺陷的转移性结直肠癌

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
PubMed 文献 · Ann Oncol · 2024-05-22

这项全球研究纳入27例携带POLE/POLD1校对缺陷(POLE/D1pd)的转移性结直肠癌(mCRC)患者,接受抗PD-L1单药±抗CTLA-4治疗,并与610例错配修复缺陷(dMMR)/微卫星高度不稳定(MSI-H)mCRC患者比较。POLE/D1pd组客观缓解率(ORR)为89%,显著高于dMMR/MSI-H组的54%(P=0.01);中位随访24.9个月后,POLE/D1pd组无进展生存(PFS)显著更优(HR=0.24,95%CI 0.08-0.74,P=0.01),总生存(OS)数值上更优但未达统计学显著(HR=0.38,95%CI 0.12-1.18,P=0.09)。

要点

  • POLE/D1pd mCRC接受ICI的ORR为89%,显著高于dMMR/MSI-H mCRC的54%(P=0.01)。
  • POLE/D1pd组PFS显著优于dMMR/MSI-H组(HR=0.24,95%CI 0.08-0.74,P=0.01)。
  • POLE/D1pd组OS数值上优于dMMR/MSI-H组,但未达统计学显著(HR=0.38,95%CI 0.12-1.18,P=0.09)。

核心结论

  • POLE/D1pd mCRC患者接受ICI治疗在肿瘤缓解和生存方面较dMMR/MSI-H mCRC患者表现出更有利的结局。

研究设计与样本

  • 全球研究纳入27例携带POLE/D1校对缺陷突变并接受抗PD-L1单药±抗CTLA-4治疗的mCRC患者。
  • 将POLE/D1pd mCRC的临床病理、基因组特征、缓解和生存结局与610例接受ICI治疗的dMMR/MSI-H mCRC患者进行比较。
  • 在7241例CRC的独立队列中进一步开展基因组分析以定义POLE和POLD1pd分子谱和突变特征。

主要发现

  • POLE/D1pd与较年轻年龄、男性、较少RAS/BRAF驱动突变及右半结肠癌为主相关。
  • POLE/D1pd mCRC的ORR为89%,dMMR/MSI-H mCRC为54%,差异显著(P=0.01)。
  • 中位随访24.9个月(四分位距11.3-43.0个月)后,POLE/D1pd组PFS显著优于dMMR/MSI-H组(HR=0.24,95%CI 0.08-0.74,P=0.01)。
  • POLE/D1pd组OS数值上优于dMMR/MSI-H组(HR=0.38,95%CI 0.12-1.18,P=0.09)。
  • 多变量分析中,POLE/D1pd与显著改善的PFS(HR=0.17,95%CI 0.04-0.69,P=0.013)和OS(HR=0.24,95%CI 0.06-0.98,P=0.047)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint inhibitors (ICIs) in POLE/D1pd mCRC are lacking and it is unknown whether outcomes may be different from mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRCs treated with ICIs. PATIENTS AND METHODS: In this global study, we collected 27 patients with mCRC harboring POLE/D1 mutations leading to proofreading deficiency and treated with anti-programmed cell death-ligand 1 alone +/- anti-cytotoxic T-lymphocyte antigen-4 agents. We collected clinicopathological and genomic characteristics, response, and survival outcomes after ICIs of POLE/D1pd mCRC and compared them with a cohort of 610 dMMR/MSI-H mCRC patients treated with ICIs. Further genomic analyses were carried out in an independent cohort of 7241 CRCs to define POLE and POLD1pd molecular profiles and mutational signatures. RESULTS: POLE/D1pd was associated with younger age, male sex, fewer RAS/BRAF driver mutations, and predominance of right-sided colon cancers. Patients with POLE/D1pd mCRC showed a significantly higher overall response rate (ORR) compared to dMMR/MSI-H mCRC (89% versus 54%; P = 0.01). After a median follow-up of 24.9 months (interquartile range: 11.3-43.0 months), patients with POLE/D1pd showed a significantly superior progression-free survival (PFS) compared to dMMR/MSI-H mCRC [hazard ratio (HR) = 0.24, 95% confidence interval (CI) 0.08-0.74, P = 0.01] and superior overall survival (OS) (HR = 0.38, 95% CI 0.12-1.18, P = 0.09). In multivariable analyses including the type of DNA repair defect, POLE/D1pd was associated with significantly improved PFS (HR = 0.17, 95% CI 0.04-0.69, P = 0.013) and OS (HR = 0.24, 95% CI 0.06-0.98, P = 0.047). Molecular profiling showed that POLE/D1pd tumors have higher tumor mutational burden (TMB). Responses were observed in both subtypes and were associated with the intensity of POLE/D1pd signature. CONCLUSIONS: Patients with POLE/D1pd mCRC showed more favorable outcomes compared to dMMR/MSI-H mCRC to treatment with ICIs in terms of tumor response and survival.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ambrosini M, Rousseau B, Manca P, et al. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024. PMID: 38777726. doi:10.1016/j.annonc.2024.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。